rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    QNCX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Citizens raises Irulya Therapeutics stock price target on share count
      Nov 16Investing.comQNCX
      Raymond James reiterates Irulya Therapeutics stock rating on BOS trial outlook
      Nov 13Investing.comQNCX
      IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

      NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious underserved diseases, today announced that senior management will participate in a Fireside Chat at the Craig-Hallum Biotech Catalyst Conference on Thursday, October 22, 2026. Following the event, a replay will be accessible by visiting the “Events” section on the “Investors” page of

      Oct 15Yahoo FinanceQNCX
      Quince Relaunches as IRulya Therapeutics with New Leadership

      Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailQNCX
      Quince Therapeutics rebrands as IRulya, names new CEO
      Oct 9Investing.comQNCX
      Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development
      Oct 9Yahoo FinanceQNCX
      Quince Therapeutics Changes Name to IRulya Therapeutics
      Oct 9Yahoo FinanceQNCX
      Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
      Oct 9Yahoo FinanceQNCX
      Raymond James initiates Quince Therapeutics stock coverage with outperform rating
      Oct 9Investing.comQNCX
      Raymond James Initiates Quince Therapeutics at Outperform With $72 Price Target

      Quince Therapeutics (QNCX) has an average rating of buy and mean price target of $74.75, according t

      Oct 9Yahoo FinanceQNCX
      Quince Shareholders Approve New Equity and Stock Plans

      Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailQNCX
      Quince Therapeutics Announces Conditional Board Restructuring Plans

      Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailQNCX
      Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX), Vir Biotechnology (VIR) and Ocugen (OCGN)

      Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailOCGNQNCXVIR
      Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)

      Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailQNCX
      Citizens reiterates Quince Therapeutics stock rating on therapy potential
      Sep 29Investing.comQNCX
      Rodman & Renshaw initiates Quince Therapeutics stock with buy rating
      Sep 24Investing.comQNCX
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Decoy Therapeutics (NASDAQ:DCOY), Greenlan
      Sep 22BenzingaQNCX
      Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline
      Sep 22Investing.comQNCX
      Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

      SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massach

      Sep 17Yahoo FinanceQNCX
      Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction
      Sep 10Investing.comQNCX
      Quince Therapeutics Faces Nasdaq Listing Compliance Challenges

      Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

      Sep 5The Globe and MailQNCX
      Quince Therapeutics to Participate in September 2026 Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026: Cantor Global Healthcare Conference: Fireside chat on Wednesday, September 9, 2026 at 2:45 p.m. ET H.C. Wainwright 28th Annual Global Inves

      Sep 3Yahoo FinanceQNCX
      Quince Therapeutics Announces Planned Presidential Leadership Transition

      Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailQNCX

      This is the newest page. Registered accounts read further back.